MilliporeSigma
HomePress ReleasesMilliporeSigma Announces a Non-Binding MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology

MilliporeSigma Announces a Non-Binding MoU with Mycenax Biotech to Drive Innovation in Bioprocessing Technology

News Release

  • MilliporeSigma announces a non-binding MoU with Mycenax Biotech to optimize bioprocessing production of life-changing biological therapies
  • Integrates company‘s BioContinuum™ Platform in Mycenax’s Contract Development and Manufacturing Services (CDMO) for maximum safety, control, transparency, and repeatability
  • Collaboration aims to enhance process intensification, advance towards BioProcessing 4.0 and continuous bioprocessing

Burlington, Massachusetts, January 24, 2024 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that the Life Science business sector entered into a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets. The MoU explores integration of the Life Science business sector’s BioContinuum™ Platform in the entire bioprocessing spectrum for Mycenax’s customers, followed by automation and digitalization of processes.

"Digital transformation in biomanufacturing is creating a paradigm shift towards a bioprocessing facility-of-the-future that is data-intensified, connected and seamless in continuous processing,” said Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector of Merck KGaA, Darmstadt, Germany. “By combining the strengths of Life Science business sector and Mycenax in Contract Development and Manufacturing Services, we aim to accelerate the development of new products and process innovations. This will enhance resilience in both research and production.”

As part of the MoU, the Life Science business sector will explore with Mycenax the provision of its extensive support including consultation, technical assistance, and training, ensuring Mycenax receives expert guidance for optimal performance. Recognizing the importance of economic viability, the collaboration will also seek ways to incorporate in-depth cost modelling for better process economics. This strategic analysis aims to enhance cost-effectiveness in next generation bioprocessing.

"Mycenax consistently seeks better solutions and areas for optimization. The integration of continuous processing and Industry 4.0 is not only a future mainstream trend but also possesses the potential for continuous growth," said Pei-Jiun Chen, Ph.D., Chairman/CEO and President of Mycenax. "The collaboration with the Life Science business sector aims to provide innovative continuous processing solutions in the market, to boost our international standing and cater to diverse biopharmaceutical needs." 

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?